Eli Lilly's drive to provide as many treatment options as possible for its weight-loss drug Zepbound has continued with the launch of new high-dose vials sold at a $150 discount to its auto ...

Eli Lilly, the manufacturer of Zepbound, made Zepbound available on its online pharmacy, LillyDirect, in August 2024. The medication is available as a single-dose vial or an auto-injector pen.

If approved, the less burdensome version of Leqembi could be used to treat patients at home or in medical facilities, help Eisai and Biogen differentiate Leqembi from Eli Lilly's recently approved ...

Eli Lilly is a global healthcare giant, generating strong growth from a diverse portfolio of blockbuster medications. Viking ...

Eli Lilly (NYSE: LLY) has transformed from a steady pharmaceutical giant into one of Wall Street’s standout growth ...

The percentage of overweight or obese adults prescribed GLP-1s jumped by almost 587% between 2019 and 2024, according to a ...

Eli Lilly and Company (NYSE:LLY) is expanding its footprint into the non-opioid pain management market in pursuit of growth opportunities. On May 27, the company announced the inking of an ...

The ACS Women Chemists Committee (WCC) and Eli Lilly and Company sponsor a program to provide funding for undergraduate, graduate, and postdoctoral female chemists to travel to meetings to present the ...

We're aiming for 100 new donors and $10,000 raised by May 31 — make your first gift today to support transparency in politics. OpenSecrets is 100% funded through donations.